Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. QDENGA (TAK-003) is most often covered alongside Drug Controller General of India (DCGI), which appears in 1 of these 1 story. We currently track 1 Biotech story that mention QDENGA (TAK-003), all published on July 25, 2026.
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. QDENGA (TAK-003) is most often covered alongside Drug Controller General of India (DCGI), which appears in 1 of these 1 story. We currently track 1 Biotech story that mention QDENGA (TAK-003), all published on July 25, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering QDENGA (TAK-003). Shared-story counts are live from our verified record — not editorial picks.
Takeda's QDENGA gains DCGI approval in India, unlocking a market that bears one‑third of global dengue cases. The vaccine's differentiation—no pre‑screening required and broad 4–60 age label—positions it strongly against legacy products like Sanofi's Dengvaxia.
Source: thenorthlines.com · dailymirror.lk
QDENGA (TAK-003) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
